Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Sell
5
MAQAF Quote, Financials, Valuation and Earnings
Last price:
$2.73
Seasonality move
:
3.86%
Day range:
$2.73 - $2.73
52-week range:
$2.73 - $4.14
Dividend yield:
9.81%
P/E ratio:
20.23x
P/S ratio:
43.33x
P/B ratio:
0.97x
Volume:
--
Avg. volume:
126
1-year change:
-28.26%
Market cap:
$4B
Revenue:
$88.4M
EPS (TTM):
$0.13
Analysts' Opinion
-
Consensus RatingAtlas Arteria has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of --, Atlas Arteria has an estimated downside of -- from its current price of $2.73.
-
Price Target UpsideAccording to analysts, the highest upside price target is -- representing -100% upside increase from its current price of $2.73.
Fair Value
-
According to the consensus of 0 analysts, Atlas Arteria has -- downside to fair value with a price target of -- per share.
MAQAF vs. S&P 500
-
Over the past 5 trading days, Atlas Arteria has underperformed the S&P 500 by -11.29% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Atlas Arteria does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Atlas Arteria has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Atlas Arteria reported revenues of --.
Earnings Growth
-
Atlas Arteria has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Atlas Arteria reported earnings per share of --.
Enterprise value:
4.9B
EV / Invested capital:
--
Price / LTM sales:
43.33x
EV / EBIT:
22.28x
EV / Revenue:
53.85x
PEG ratio (5yr expected):
1.01x
EV / Free cash flow:
--
Price / Operating cash flow:
--
Enterprise value / EBITDA:
18.40x
Gross Profit (TTM):
$79.7M
Return On Assets:
3.63%
Net Income Margin (TTM):
--
Return On Equity:
4.67%
Return On Invested Capital:
3.68%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-12-31 | 2012-12-31 | 2013-12-31 | 2012-12-31 | 2013-12-31 | |
| Income Statement | ||||||
| Revenue | $90.7M | $91.8M | -- | $93.3K | $214.3K | |
| Gross Profit | $90.7M | $86.4M | -- | $93.3K | $214.3K | |
| Operating Income | -$54.6M | $895.1K | -$32.1M | -$51.6M | $45.3M | |
| EBITDA | -$179.2M | -$8.9M | -$32.1M | -$51.6M | $45.3M | |
| Diluted EPS | -$0.60 | -$0.25 | $2.67 | -$0.10 | $0.01 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $133.7M | $152.3M | $142.1M | $118.9M | $182.1M | |
| Total Assets | $3.8B | $3.9B | $3.5B | $5.5B | $5.3B | |
| Current Liabilities | $58M | $76.8M | $76.4M | $80.6M | $80.5M | |
| Total Liabilities | $1.2B | $1.2B | $1.2B | $1.2B | $1.2B | |
| Total Equity | $2.6B | $2.6B | $2.3B | $4.3B | $4.1B | |
| Total Debt | $1.1B | $1.2B | $1.1B | $1.1B | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2011-06-30 | 2012-06-30 | 2013-06-30 | 2012-06-30 | 2013-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -$3.4M | -$2.3M | -$63.8M | -$1.1M | -$65.9M | |
| Cash From Financing | -$58.5M | -$47M | -$41.6M | -$23.2M | -$10.7M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
MAQAF
Sector
Market Cap
$4B
$764.1M
Price % of 52-Week High
65.85%
78.36%
Dividend Yield
9.81%
0%
Shareholder Yield
--
2.32%
1-Year Price Total Return
-28.26%
-1.72%
Beta (5-Year)
1.196
0.899
Dividend yield:
9.81%
Annualized payout:
$0.26
Payout ratio:
192.98%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.95
200-day SMA
Sell
Level
$3.34
Bollinger Bands (100)
Sell
Level
3.03 - 3.45
Chaikin Money Flow
Sell
Level
-78.3K
20-day SMA
Sell
Level
$3.07
Relative Strength Index (RSI14)
Sell
Level
15.13
ADX Line
Sell
Level
13.78
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$3.16
MACD (12, 26)
Sell
Level
-0.09
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
174.9K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8548)
Buy
CA Score
(Annual)
Level (0.2024)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-2.1113)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Atlas Arteria is a global toll-road investor created out of the reorganisation of Macquarie Infrastructure Group in 2010. The firm's main asset is a 31.1% stake in Autoroutes Paris-Rhin-Rhone, or APRR. APRR owns concessions to toll more than 2,300 kilometres of motorways in eastern France, most ending late 2035. The firm also wholly owns the Dulles Greenway toll road in the U.S.
Stock Forecast FAQ
In the current month, MAQAF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MAQAF average analyst price target in the past 3 months is --.
-
Where Will Atlas Arteria Stock Be In 1 Year?
According to analysts, the consensus estimate is that Atlas Arteria share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Atlas Arteria?
Analysts are divided on their view about Atlas Arteria share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Atlas Arteria is a Sell and believe this share price will rise from its current level to --.
-
What Is Atlas Arteria's Price Target?
The price target for Atlas Arteria over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MAQAF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Atlas Arteria is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MAQAF?
You can purchase shares of Atlas Arteria via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Atlas Arteria shares.
-
What Is The Atlas Arteria Share Price Today?
Atlas Arteria was last trading at $2.73 per share. This represents the most recent stock quote for Atlas Arteria. Yesterday, Atlas Arteria closed at $2.73 per share.
-
How To Buy Atlas Arteria Stock Online?
In order to purchase Atlas Arteria stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Sell
40
MSTR alert for Dec 24
MicroStrategy [MSTR] is up 8.05% over the past day.
Sell
26
NUTX alert for Dec 24
Nutex Health [NUTX] is down 0.76% over the past day.
Sell
48
VRNA alert for Dec 24
Verona Pharma PLC [VRNA] is down 0.62% over the past day.
